Oncology
From preclinical toxicology to clinical safety: The path for...
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
Oncology
Advancing the case for cell and gene therapies
After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
News
Jeito closes 'record' $1.2bn Europe-focused biopharma fund
Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.
Oncology
Radiopharmaceutical development is accelerating. Preclinical...
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
News
Gilead strikes again, penning $5bn deal to buy Tubulis
Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
